Cargando…
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Alzheimer’s disease and Lewy body diseases are the most common causes of neurodegeneration and dementia. Amyloid-beta (Aβ) and alpha-synuclein (αSyn) are two key proteins involved in the pathogenesis of these neurodegenerative diseases. Immunotherapy aims to reduce the harmful effects of protein acc...
Autores principales: | Nimmo, Jacqui Taryn, Kelly, Louise, Verma, Ajay, Carare, Roxana O., Nicoll, James A. R., Dodart, Jean-Cosme |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441015/ https://www.ncbi.nlm.nih.gov/pubmed/34539340 http://dx.doi.org/10.3389/fnins.2021.733857 |
Ejemplares similares
-
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
por: Nimmo, Jacqui T., et al.
Publicado: (2020) -
Correction: Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
por: Nimmo, Jacqui T., et al.
Publicado: (2023) -
Peri‐arterial pathways for clearance of α‐Synuclein and tau from the brain: Implications for the pathogenesis of dementias and for immunotherapy
por: Nimmo, Jacqui, et al.
Publicado: (2020) -
Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
por: Nimmo, Jacqui T., et al.
Publicado: (2021) -
Editorial: Clearance Pathways for Amyloid-β. Significance for Alzheimer's Disease and Its Therapy
por: Carare, Roxana O.
Publicado: (2017)